296 related articles for article (PubMed ID: 35951282)
1. Extracellular vesicle-mediated immunoregulation in cancer.
Yamamoto T; Yamamoto Y; Ochiya T
Int J Hematol; 2023 May; 117(5):640-646. PubMed ID: 35951282
[TBL] [Abstract][Full Text] [Related]
2. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
3. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
[TBL] [Abstract][Full Text] [Related]
4. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
Ricklefs FL; Alayo Q; Krenzlin H; Mahmoud AB; Speranza MC; Nakashima H; Hayes JL; Lee K; Balaj L; Passaro C; Rooj AK; Krasemann S; Carter BS; Chen CC; Steed T; Treiber J; Rodig S; Yang K; Nakano I; Lee H; Weissleder R; Breakefield XO; Godlewski J; Westphal M; Lamszus K; Freeman GJ; Bronisz A; Lawler SE; Chiocca EA
Sci Adv; 2018 Mar; 4(3):eaar2766. PubMed ID: 29532035
[TBL] [Abstract][Full Text] [Related]
5. Extracellular vesicle-based checkpoint regulation and immune state in cancer.
Mortezaee K; Majidpoor J
Med Oncol; 2022 Sep; 39(12):225. PubMed ID: 36175741
[TBL] [Abstract][Full Text] [Related]
6. Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer.
Dou X; Hua Y; Chen Z; Chao F; Li M
Clin Exp Immunol; 2022 May; 207(3):307-317. PubMed ID: 35553630
[TBL] [Abstract][Full Text] [Related]
7. Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model.
Veerman RE; Akpinar GG; Offens A; Steiner L; Larssen P; Lundqvist A; Karlsson MCI; Gabrielsson S
Cancer Immunol Res; 2023 Feb; 11(2):217-227. PubMed ID: 36546872
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicle-based drug delivery in cancer immunotherapy.
Najafi S; Majidpoor J; Mortezaee K
Drug Deliv Transl Res; 2023 Nov; 13(11):2790-2806. PubMed ID: 37261603
[TBL] [Abstract][Full Text] [Related]
9. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of T-cell-suppressive PD-L1
Baur R; Karl F; Böttcher-Loschinski R; Stoll A; Völkl S; Gießl A; Flamann C; Bruns H; Schlötzer-Schrehardt U; Böttcher M; Schewe DM; Fischer T; Jitschin R; Mackensen A; Mougiakakos D
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898735
[TBL] [Abstract][Full Text] [Related]
11. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
[TBL] [Abstract][Full Text] [Related]
12. Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy.
Xu F; Jiang D; Xu J; Dai H; Fan Q; Fei Z; Wang B; Zhang Y; Ma Q; Yang Q; Chen Y; Ogunnaike EA; Chu J; Wang C
Cell Rep; 2023 Oct; 42(10):113138. PubMed ID: 37738123
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles.
Tian T; Liang R; Erel-Akbaba G; Saad L; Obeid PJ; Gao J; Chiocca EA; Weissleder R; Tannous BA
ACS Nano; 2022 Feb; 16(2):1940-1953. PubMed ID: 35099172
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
Zhang Y; Ge T; Huang M; Qin Y; Liu T; Mu W; Wang G; Jiang L; Li T; Zhao L; Wang J
Int J Nanomedicine; 2023; 18():49-63. PubMed ID: 36636644
[TBL] [Abstract][Full Text] [Related]
15. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
[TBL] [Abstract][Full Text] [Related]
16. Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles.
Khan A; Di K; Khan H; He N; Li Z
Biosensors (Basel); 2022 Apr; 12(5):. PubMed ID: 35624582
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated Fibroblast-derived Extracellular Vesicles Mediate Immune Escape of Bladder Cancer via PD-L1/PD-1 Expression.
Feng R; Li Z; Ge G; Wang C; Jia Y; Ouyang J
Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1410-1420. PubMed ID: 36852791
[TBL] [Abstract][Full Text] [Related]
18. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
Signorelli D; Ghidotti P; Proto C; Brambilla M; De Toma A; Ferrara R; Galli G; Ganzinelli M; Lo Russo G; Prelaj A; Occhipinti M; Viscardi G; Capizzuto V; Pontis F; Petraroia I; Ferretti AM; Colombo MP; Torri V; Sozzi G; Garassino MC; Jachetti E; Fortunato O
Front Immunol; 2022; 13():987639. PubMed ID: 36203609
[TBL] [Abstract][Full Text] [Related]
19. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
20. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
